Results From Two Phase II Trials Add to Understanding of Ticagrelor (BRILINTA(TM)) and How it Works in the Body

Update: Brilinta (ticagrelor) Now FDA Approved - July 20, 2011

Ticagrelor data presented at the American Heart Association Scientific Sessions

ORLANDO, Fla., Nov. 18 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE:AZN) today announced the results of the phase II studies, ONSET/OFFSET and RESPOND for ticagrelor (BRILINTA(TM)) at the annual American Heart Association (AHA) Scientific Sessions in Orlando, FL,(1,2) with ONSET/OFFSET study results being simultaneously published in the medical journal Circulation.(3)
 

The ONSET/OFFSET data showed that treatment with ticagrelor (BRILINTA(TM)) achieved a more rapid onset of antiplatelet effect (41% IPA vs. 8% at 30 minutes; P<0.0001), greater inhibition of platelet aggregation (IPA) that was sustained during maintenance phase of treatment (IPA; P<0.0001 at all times) and faster offset IPA compared to clopidogrel, in patients with stable coronary artery disease (CAD) on aspirin therapy.
 

Platelets initiate the formation of blood clots by sticking together (clumping or aggregating), a process called platelet aggregation. Inhibition of platelet aggregation (IPA) is the prevention of clumping of platelets in the blood, which reduces the risk of clot formation and subsequent thrombotic events.
 

These results were achieved using ticagrelor 180 mg loading dose followed by 90 mg twice daily, as studied in PLATO (A Study of Platelet Inhibition and Patient Outcomes), compared to clopidogrel 600 mg loading dose followed by 75 mg once daily dose.(1)
 

  Key findings:(1)
  --  Greater IPA occurred with ticagrelor compared to clopidogrel at time
      points of 0.5, 1, 2, 4, 8 and 24 hours after patients received initial
      treatment dose and at 6 weeks (P<0.0001 for all)
  --  At 2 hours after patients received initial treatment dose a greater
      proportion of patients achieved >50% IPA (98% vs. 31%, P<0.0001) and
      >70% IPA (90% vs. 16%, P<0.0001) in the ticagrelor versus clopidogrel
      group, respectively.
  --  A faster offset of IPA occurred with ticagrelor than clopidogrel (4 to
      72 hour slope (IPA (%)/hour): -1.037 vs. -0.482, P<0.0001). At 24 h
      after last treatment dose, mean IPA was 58% for ticagrelor vs. 52% for
      clopidogrel (P=NS). This level of IPA with ticagrelor is equivalent to
      the levels patients achieved on maintenance clopidogrel therapy in the
      study

  --  IPA for ticagrelor on day 3 after the last dose was comparable to
      clopidogrel at day 5;

In the Phase II RESPOND study, the antiplatelet effect of ticagrelor on both clopidogrel responders and non-responders were evaluated in 98 patients with stable coronary artery disease.
 

Among patients identified as clopidogrel responders, switching from clopidogrel to ticagrelor resulted in a mean IPA increase of 26% and switching from ticagrelor to clopidogrel resulted in a mean IPA decrease of 24%, suggesting that patients can be switched from clopidogrel to ticagrelor without interruption of antiplatelet effect.
 

Among patients identified as clopidogrel non-responders, the primary endpoint (difference in the proportion of non-responders on ticagrelor versus clopidogrel who achieved >10% final extent IPA) was not statistically significant. This result derives from the higher than expected response to clopidogrel after 14 days of treatment in patients initially defined as clopidogrel non-responders. However, the nominal p-values for this difference at the >30% and >50% IPA levels were both <0.001. Additional exploratory and ad-hoc analyses showed that at steady state (Day 14), the IPA response to ticagrelor was consistently higher compared with clopidogrel at all post dose assessments with nominal p-values <0.05 for all assessments. The findings from RESPOND demonstrated that due to the variability of clopidogrel response, identification of clopidogrel non-responders is difficult.
 

"In acute coronary syndromes, a rapid and sustained antiplatelet effect is desirable since patients are at highest risk for events soon after they present with symptoms," commented Dr. Paul A. Gurbel, Director of the Sinai Center for Thrombosis Research, Baltimore, MD, and Principal Investigator of both the ONSET/OFFSET and RESPOND studies. "Today's data add to the growing body of evidence to understand how ticagrelor works, and how it affects platelets in the body."
 

About the ONSET/OFFSET Study(1)
 

The ONSET/OFFSET trial was a randomized multicenter, double-blind, parallel-group study of patients with stable CAD on aspirin therapy. This trial was designed to assess the onset and rate of offset of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable CAD. 123 patients with stable CAD on aspirin therapy received ticagrelor (180 mg load, then 90 mg twice daily [n=57]), clopidogrel (600 mg load, then 75 mg once daily [n=54] or placebo (n=12) for 6 weeks. The total duration of the study for each patient was approximately 10 weeks.
 

About the RESPOND Study(2)
 

The RESPOND study was a phase II, randomized, multicenter, international trial designed to assess the effect of ticagrelor in stable CAD patients (n=98) responsive and non-responsive to clopidogrel. In a 2-way crossover design, non-responders (n=41) and responders (n=57) randomly received either clopidogrel (600 mg load, then 75 mg once daily) or ticagrelor (180 mg load, then 90 mg twice daily) for 14 days during period one. In Period 2, all non-responders switched treatment and half of the responders continued with the same therapy while the remaining switched. The study set out to investigate the antiplatelet effect of ticagrelor in patients non-responsive to clopidogrel and examined the effect after switching between agents.
 

About Coronary Artery Disease (CAD)
 

Coronary artery disease, also called coronary heart disease, is most often caused by atherosclerosis, and can lead to acute coronary syndrome (ACS).
 

About Ticagrelor
 

Ticagrelor (BRILINTA(TM)) is an investigational oral antiplatelet treatment for acute coronary syndromes (ACS) and the first in a new chemical class, the CPTPs (cyclo-pentyl-triazolo-pyrimidines). Ticagrelor is chemically distinct from the thienopyridines, such as clopidogrel and prasugrel.
 

AstraZeneca has proposed the name BRILINTA(TM) in the US. If approved by the FDA, it will serve as the trade name for ticagrelor. BRILINTA is a trademark of the AstraZeneca group of companies.
 

About AstraZeneca
 

AstraZeneca is engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and in the supply of healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with global healthcare sales of $31.6 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. In the United States, AstraZeneca is a $13.5 billion dollar healthcare business.
 

For more information about AstraZeneca in the US or our AZ&Me(TM) Prescription Savings programs, please visit: www.astrazeneca-us.com.
 

References
 

(1.) Gurbel P et al, Randomised Double-Blind Study to Assess the Onset and Offset of the Antiplatelet Effects of Ticagrelor versus Clopidogrel in Patients with Stable Coronary Artery Disease. Presentation at AHA 2009.
 

(2.) Gurbel P et al, The Effect of Ticagrelor in Stable Coronary Artery Disease Patients Nonresponsive to Clopidogrel: The RESPOND Study. Presentation at AHA 2009.
 

Source: AstraZeneca

CONTACT: U.S. Media Inquiries: Julia Walker, +1-302-885-5172, mob:
+1-610-350-8240, Media Inquiries: Chris Sampson, +44 20 7304 5130 (24 hours),
Sarah Lindgreen +44 20 7304 5033 (24 hours), Neil McCrae, +44 207 304 5045
(24 hours), Global Media Inquiries: Michele Pelkowski, +1-302-885-4055, mob:
+1-610-812-3716, Investor Inquiries US: Ed Seage, +1-302-886-4065, mob:
+1-302-373-1361, Jorgen Winroth, +1-212-579-0506, mob: +1 917 612 4043,
Investor Inquiries UK: Jonathan Hunt, +44 207 304 5087, mob: +44 7775 704032,
Karl Hard, +44 207 304 5322, mob: +44 7789 654364, Clive Morris, +44 207 304
5084, mob: +44 7710 031012
 

Web Site: http://www.astrazeneca-us.com/
 

Posted: November 2009

View comments

Hide
(web2)